» Articles » PMID: 21205680

Registry Studies of Long-term Multiple Sclerosis Outcomes: Description of Key Registries

Overview
Journal Neurology
Specialty Neurology
Date 2011 Jan 6
PMID 21205680
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple sclerosis (MS) registries can provide valuable insights into the natural history of MS. Key observational findings of the registries include MS patient disability progression rate, predictors of increased disability, and changes in lifespan. MS registries have been established in Canada, the United States, and Europe, some of which have existed for decades. Recommendations for registry use and improvement based on a review of a selection of MS registries from these countries are presented.

Methods: A panel of experts analyzed the current status of a number of the established MS registries and made recommendations on their usefulness and on improvements for the creation of future MS registries.

Results: Improved inter-registry consistency in order to better compare and contrast the results of different registries was advocated. To follow the course of MS, the initiation of a prospective, complete, verifiable database of patients with clinically isolated syndrome was also recommended. Time to Expanded Disability Status Scale 6 was supported over mortality as the central endpoint of a registry study, because it can be detected earlier in the course of the disease than mortality.

Conclusions: The data collected from registries are considered valuable in understanding MS, despite difficulties with registries such as a lack of consistency between their databases.

Citing Articles

The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS).

Rammohan K, Halper J, Lang S, Murphy S, Patton L, Goodman C Int J MS Care. 2022; 23(6):269-275.

PMID: 35035298 PMC: 8745232. DOI: 10.7224/1537-2073.2021-021.


Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.

Vrenken H, Jenkinson M, Pham D, Guttmann C, Pareto D, Paardekooper M Neurology. 2021; 97(21):989-999.

PMID: 34607924 PMC: 8610621. DOI: 10.1212/WNL.0000000000012884.


[Real-world evidence : Benefits and limitations in multiple sclerosis research].

Ziemssen T, Rothenbacher D, Kuhle J, Berger T Nervenarzt. 2017; 88(10):1153-1158.

PMID: 28776214 DOI: 10.1007/s00115-017-0387-y.


Landscape of MS patient cohorts and registries: Recommendations for maximizing impact.

Bebo Jr B, Fox R, Lee K, Utz U, Thompson A Mult Scler. 2017; 24(5):579-586.

PMID: 28279128 PMC: 5987851. DOI: 10.1177/1352458517698250.


Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach.

Ziemssen T, Kern R, Thomas K BMC Neurol. 2016; 16:124.

PMID: 27484848 PMC: 4971685. DOI: 10.1186/s12883-016-0639-7.